Minimally Invasive Treatment for People with Mitral Regurgitation Disorder

By NoCamels Team (May 26, 2013)

Every year 70,000 people worldwide are denied life-saving open heart surgery for a life threatening condition called mitral regurgitation, a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood.

The mitral valve acts as the heart’s gatekeeper. It regulates the flow of blood between the two chambers of the left side of the heart. When the valve’s two leaflets fail to close completely, blood regurgitates into the left atrium (hence the condition’s name), decreasing blood flow to the rest of the body. To compensate, the heart pumps harder, an action that may eventually lead to heart failure.

Israeli company MitrAssist is working on an implant which would be placed on top of the native valve and then anchored securely to work in unison with the body’s own valve. “Our ‘valve-in-valve’ approach is designed to prevent leakage and restore normal blood flow,” MitrAssist’s CEO, Gil Naor tells NoCamels. “Our valve works with the body rather than against it.”

Read the full article on NoCamels.

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize